세계 세포 치료 시장 규모는 2023년 46억 7,000만 달러에서 예측 기간 동안 13.56%의 CAGR을 기록하며 2031년에는 129억 3,000만 달러에 달할 것으로 예상됩니다.
주요 촉진요인으로는 만성질환 유병률 증가, R&D 투자 증가, 세포 치료 기술의 지속적인 발전, 우호적인 규제 환경, 협력적 파트너십, 응용 분야 확대 등을 들 수 있습니다. 수요 확대의 배경에는 전 세계적으로 만성질환의 증가가 있습니다. 이러한 질병이 증가함에 따라 혁신적이고 효과적인 치료법에 대한 수요가 증가하고 있으며, 세포 치료는 유망한 솔루션으로 자리매김하고 있습니다.
만성질환의 유병률 증가는 세계 세포 치료 시장의 중요한 동인이 되고 있습니다. 최소 한 가지 이상의 만성질환을 앓고 있는 50세 이상 인구는 2020년 7,152만 2,000명에서 2050년에는 99.5% 증가한 1억 4,266만 명에 달할 것으로 예측됩니다. 이러한 인구 통계학적 변화로 인해 진보적이고 효과적인 치료법이 절실히 요구되고 있으며, 세포 치료가 유망한 해결책으로 떠오르고 있습니다. 또한, 2020년 783만 400명에서 2050년에는 91.16% 증가한 1,496만 8,000명의 다발성 질환 환자가 발생할 것으로 예상되며, 이는 고령화 사회가 직면한 복잡한 건강 문제를 더욱 부각시키고 있습니다. 증가하는 건강 부담에 대응하기 위해 혁신적인 세포 치료에 대한 수요가 증가하고 있으며, 시장은 진화하는 의료 환경에 대응하고 만성질환 관리를 위한 맞춤형 솔루션을 제공할 수 있는 입지를 확보하게 되었습니다.
대기업들은 첨단 제조시설을 설립하고 세포 치료에 대규모 투자를 하고 있습니다. 이러한 노력은 세포 치료의 잠재력에 대한 자신감을 반영하는 것으로, 세계 세포 치료 시장의 중요한 촉진제 역할을 하고 있습니다. 최첨단 제조 시설에 대한 대규모 투자는 생산 능력과 확장성을 향상시켜 세포 기반 치료제를 보다 효율적이고 광범위하게 제공할 수 있게 해줍니다. 업계 선두주자들의 적극적인 접근 방식은 혁신을 촉진하고 세계 세포 치료 시장의 성장과 성숙에 기여하고 있으며, 헬스케어 분야의 변혁을 주도하는 힘으로 자리매김하고 있습니다.
세계 각국 정부는 세계 세포 치료 시장의 성장을 촉진하기 위해 주요 기업들과 협력하고 있습니다. 이러한 파트너십은 정부의 지원과 전문 지식을 활용하여 세포 치료의 연구, 개발 및 접근성을 촉진하는 것을 목표로 합니다. 이러한 협력을 통해 정책 입안자들은 혁신에 도움이 되는 환경을 조성하고, 규제 당국의 승인을 가속화하며, 이러한 첨단 의료 개입의 보급을 보장하기 위해 노력하고 있습니다. 정부와 주요 업계 관계자들 간의 시너지 효과는 헬스케어에 혁명을 일으키고, 전 세계적인 문제를 해결하기 위한 세포 치료의 잠재력을 극대화하기 위한 공동의 노력을 반영하고 있습니다.
세계 세포 치료 시장을 조사했으며, 시장 정의와 개요, 시장 규모 추이 및 예측, 각종 부문별·지역별 상세 분석, 산업 구조, 시장 성장에 영향을 미치는 요인 분석, 사례 연구, 경쟁 상황, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.
Global cell therapy market size was valued at USD 4.67 billion in 2023, expected to reach USD 12.93 billion in 2031, with a CAGR of 13.56% for the forecast period between 2024 and 2031. Several factors propel the global cell therapy market, creating an exciting and high-potential environment. Key drivers include the rising prevalence of chronic diseases, increasing investments in research and development, continuous advancements in cell therapy technologies, a supportive regulatory environment, collaborative partnerships, and growing applications. A prominent force behind the growing demand is the increasing prevalence of chronic diseases worldwide. As these conditions become more prevalent, there is an increasing demand for innovative and effective treatments, positioning cell therapy as a promising solution.
Pharmaceutical companies and research institutions are investing significant amounts in exploring the vast potential of cell therapies. This financial commitment fosters groundbreaking discoveries and accelerates the development of novel treatments. Advancements in cell therapy technologies are further contributing to this dynamic landscape. Breakthrough technologies such as CRISPR gene editing are enhancing the precision and efficacy of cell therapies, opening new possibilities for therapeutic interventions across various medical domains in global cell therapy market. A supportive regulatory environment acts as a catalyst, streamlining approval processes and encouraging companies to invest in the development of cell-based treatments, boosting the growth of the global cell therapy market. Collaborative partnerships between pharmaceutical/biotech firms, and academic institutions leverage collective strengths, fostering innovation and expediting the commercialization of promising therapies. As cell therapy applications continue to broaden from oncology to neurodegenerative diseases, the global awareness and acceptance of these innovative treatments are on the rise.
The increasing prevalence of chronic diseases is a significant catalyst for the global cell therapy market. As the population aged 50 and above faces a staggering increase in the incidence of at least one chronic disease, the numbers are projected to surge by 99.5%, reaching 142.66 million by 2050 from 71.522 million in 2020. The demographic shift signifies an urgent need for advanced and effective therapeutic interventions, with cell therapy emerging as a promising solution. Moreover, the projection of a 91.16% increase in individuals with multimorbidity-from 7.8304 million in 2020 to 14.968 million in 2050, highlights the complexity of health challenges an aging population faces. In response to the growing health burden, the demand for innovative cell therapies is rising, positioning the market to address the evolving healthcare landscape and offer targeted solutions for chronic disease management.
Leading companies are investing substantially in cell therapy by establishing state-of-the-art manufacturing facilities. The initiative reflects their confidence in cell therapies' potential and is a significant driver for the global cell therapy market. Significant investments in advanced production facilities enable increasing production capacity and scalability, resulting in a more efficient and widespread delivery of cell-based treatments. The proactive approach by major industry players fosters innovation and contributes to the overall growth and maturity of the global cell therapy market, solidifying their position as a transformative force in healthcare.
For instance, in October 2023, Bayer AG revealed its inaugural cell therapy launch facility in Berkeley, California, marking a pivotal step in their global initiative to provide cell therapies to patients. The USD 250 million, 100,000-square-foot facility is designed to meet the demand for materials in late-stage clinical trials and the potential commercial launch of BlueRock Therapeutics' bemdaneprocel (BRT-DA01), an investigational cell therapy under assessment for Parkinson's disease treatment. The establishment of the cutting-edge facility underscores Bayer's commitment to advancing cell therapies on a global scale and signifies a significant investment in the future of innovative medical solutions.
Governments around the globe are collaborating with major companies to stimulate the growth of the global cell therapy market. These partnerships aim to leverage governmental support and expertise to advance research, development, and accessibility of cell therapies. By fostering such collaborations, policymakers seek to create a conducive environment for innovation, accelerate regulatory approvals, and ensure widespread adoption of these advanced medical interventions. The synergy between governments and key industry players reflects a shared commitment to realize the full potential of cell therapies in revolutionizing healthcare and addressing challenges on a global scale.
In September 2023, the United States government unveiled new measures as part of the Cancer Moonshot Initiative, a focal point in the battle against cancer. The initiative was led by President through the collaborative entity "CancerX," aiming to reduce the U.S. cancer death rate by 50% before 2047. The initiative includes prominent pharmaceutical companies and their partnership with digital healthcare solution providers such as Amazon and Intel. The Moffitt Cancer Center in Florida and the Digital Medicine Society (DiMe), a global non-profit of digital medicine experts, lead the effort.
The global cell therapy market is witnessing a growing demand for T-cell therapy. The innovative approach has gained prominence due to its remarkable success in treating certain cancers, especially hematologic malignancies. As clinical trials demonstrate its efficacy and safety, the demand for T-cell therapy is increasing. Patients, healthcare providers, and pharmaceutical companies recognize its potential to revolutionize cancer treatment by leveraging the body's immune system. The increasing demand is propelling research, development, and investment in T-cell therapies, contributing to the dynamic growth of global cell therapy market.
In March 2023, Thermo Fisher Scientific and Arsenal Biosciences, Inc., American companies, announced their strategic partnership to advance the manufacturing processes for novel cancer treatments. The collaboration emphasizes research and process development to establish a robust manufacturing framework for their cutting-edge, programmable autologous T cells designed for cancer treatment.
The global cell therapy market is poised for a promising future, driven by a convergence of factors highlighting its potential to revolutionize healthcare. Advancements in cell therapy technologies, including precision-enhancing techniques like CRISPR gene editing, are increasing the efficacy and scope of treatments. The rising prevalence of chronic diseases, such as cancer and autoimmune disorders, create a compelling need for innovative therapeutic solutions, positioning cell therapy at the forefront of medical breakthroughs. Collaborative partnerships between pharmaceutical companies, biotech firms, and academic institutions are accelerating research and development efforts, fostering a dynamic environment of innovation. Supportive regulatory frameworks and increasing stakeholder awareness contribute towards a favorable landscape for the market's growth. With expanding applications across diverse medical domains and a global commitment to addressing unmet healthcare needs, the cell therapy market is poised to play a pivotal role in shaping the future of healthcare.
Numerous major companies are actively forming collaborations in the global cell therapy market. These strategic partnerships facilitate the pooling of resources, expertise, and technologies to drive innovation and expedite the development of advanced cell-based therapies. By joining forces, these companies enhance their capabilities in research, clinical trials, and manufacturing processes, ultimately contributing to the evolution and expansion of the cell therapy market.
For instance, in August 2023, Astellas Pharma Inc. and Poseida Therapeutics, Inc. unveiled a strategic investment to bolster Poseida's pioneering efforts in redefining cancer cell therapy. In the financial arrangement, Astellas is set to invest a total of USD 50 million, comprising a USD 25 million acquisition of 8,333,333 shares of Poseida's common stock (representing around 8.8% of the total outstanding common stock) at USD 3.00 per share through a private placement. Additionally, a one-time payment of USD 25 million secures Astellas an exclusive negotiation and first refusal right to license Poseida's clinical stage program, P-MUC1C-ALLO1. The program involves the development of an allogeneic CAR-T cell therapy targeting multiple solid tumor indications.
All segments will be provided for all regions and countries covered:
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.